Physicians are faced with a burgeoning literature of economic studies. However, most physicians have little training in evaluating economic research. Economic studies involve a comparison of the costs and benefits of alternative treatment options. To be of use for medical decision making, they should meet appropriate methodological standards. These include clear specification of the research question and the perspective from which the study is being undertaken, comparison of relevant treatment options, identification and quantification of all important costs and benefits, the use of discounting to allow for time preferences for costs and benefits, and sensitivity analyses to test the robustness of the study's results. Unfortunately, not all adhere to these principles. Physicians need to be able to understand and critically assess the quality of economic studies, and the applicability of the results to their own situation, in order to participate in medical policy decisions.
Introduction
The expenditures associated with medical practice are coming under increased scrutiny. At a time when governments are trying to contain costs, an aging population is increasingly demanding access to ever more complex and expensive health care technologies. Both public and private payers are demanding increased efficiency and 'value for money' in the provision of health care services. In response, there has been an exponential growth in studies evaluating the cost-effectiveness of medical procedures. The result is that clinicians reading medical journals are faced increasingly with the need to appraise this literature.
Physicians have traditionally had little interest or training in health economics. Therefore, they may be tempted to skip to the 'bottom line' of an economic study. However, this practice can be dangerous because it may lead to inappropriately applying the results of a poor study, or to using data that is not applicable in their setting. Lack of knowledge and understanding of the health economics literature leaves doctors uninformed when dealing with those who decide the funding of new treatments. Therefore, it is important for clinicians to be able to understand, appraise, and apply the results of economic studies to their own practices.
Study framework
Economic evaluation provides a framework to systematically compare the costs and outcomes of alternative health care interventions. This provides useful information to purchasers who must make decisions about which technologies to fund.
The first step in reading an economic study is to identify the research question being addressed. The essential elements of the question are: 1) the alternatives being compared, 2) the perspective of the analysis, and 3) the outcome being measured. The outcome largely determines the analytic technique. Careful consideration of these components can indicate whether a study is likely to be relevant to an individual physician's practice.
Comparison of alternatives
A full economic evaluation should include a comparison of at least two alternative interventions, and it should fully describe these alternatives. However, there can be different comparators in different situations. If appropriate, it should explore a 'do nothing' alternative to determine whether there should be any intervention at all for the condition. Any alternative treatments already in use for the condition should also be assessed. In addition, guidelines have proposed that the cheapest option [1] , or the 'most used' option [2] should be included. The reader must decide whether any appropriate alternative has been excluded.
Perspective
The perspective of an analysis will affect the range of costs and benefits estimated, and ultimately the conclusions of the evaluation. Ideally, a full economic evaluation should consider the costs and benefits to all sectors of society affected by the interventions. However, evaluations often are carried out from one very relevant perspective such as that of the providers or purchasers of health care. The most economical management strategy from the perspective of a hospital may not be the same as that from the perspective of the entire health care system. For example, a program of early discharge after major surgery might save a hospital money, but increased costs for home care services may offset these savings. On the other hand, the perspective of the health care system may ignore important costs to social service agencies, or to family members who may lose wages staying home to provide care [3] . One solution to this problem is to take a broader perspective, but also to present the costs and benefits broken down into the component parts of that broader perspective.
Analytic technique
There are four types of commonly used economic evaluations (Table 1) . Each involves a comparison of both the costs and consequences of alternative interventions. The main differences between them are the methods used to measure the consequences.
Cost-minimization analysis
Also called a cost-analysis, cost-minimization analysis is the simplest form of economic evaluation. This type of study assumes that the outcomes or effectiveness of the interventions are equal. Resource utilization is the only significant difference between the options. The direct costs associated with each intervention are compared, and the least costly strategy is the preferred choice. No assessment of the consequences of treatment is required. While there are some examples in the oncology literature addressing staging procedures [4, 5] , radiotherapy techniques [6] [7] [8] , and systemic therapy [9] , cost-minimization studies are not common because cancer treatments rarely produce equivalent survival or quality of life.
Cost-effectiveness analysis
If the interventions being assessed are not of equal effectiveness, a more sophisticated analysis is required. Cost-effectiveness analysis includes a comparison of outcomes as well as costs. In this form of analysis, the effectiveness of alternatives is measured in natural units, such as life years gained, cases successfully treated, or cases averted. These outcomes then are related to the direct costs of the procedure by calculating ratios of cost per unit of effectiveness, such as cost per life year gained.
Cost-effectiveness analysis has the advantage of being easily understandable. As a result, it is the most common approach to economic evaluation in healthcare [10] . However, only one measure of effectiveness can be related to the cost of the interventions. A cost per life year gained looks only at survival, but not at toxicity, inconvenience, or effects on quality of life. These are also important considerations in cancer treatment. For Table I . Types of economic analyses.
Cost-minimization analysis

Cost-effectiveness analysis
Cost-utility analysis Compares strategies of equal effectiveness to determine which is least expensive.
Compares ratios of the incremental cost over the incremental effectiveness of alternative strategies.
Compares ratios of the incremental cost over the incremental utility. The utility is a measure of the value attributed to a health state, usually measured in quality adjusted life years (QALY).
Cost-benefit analysis Assigns monetary value to the health benefits of an intervention. If the cost/benefit ratio is < 1, the intervention is attractive.
example, surgery versus radiation for the primary treatment of a specific cancer can be compared in terms of their costs per life year gained, but this may lead to an invalid conclusion if their effects on quality of life are very different. Therefore, cost-effectiveness analysis can help choose between similar treatments for a specific disease, but not for choices across dissimilar treatments and conditions.
Cost-utility analysis
A cost-utility analysis is similar to a cost-effectiveness analysis. The main difference is that cost-utility combines mortality and morbidity data into a single multidimensional measure, usually a quality adjusted life year (QALY) [11] . The QALY is a measure of the quantity of life gained by a treatment, weighted by the quality of that life. Because the QALY is not disease-specific, it allows comparison of the relative efficiency of health care interventions for different conditions. Each of these analytic techniques has its place. While cost-utility analysis is ideal for comparing toxic treatment options, a cost-effectiveness analysis may be adequate when deciding between two diagnostic strategies. Quality of life is approximated by a utility, which is a measure of preference for a given health state rated on a scale from 0 (the worst imaginable health state) to 1 (perfect health). According to 'expected utility theory', a utility is derived most accurately by 'standard gamble' techniques, although other techniques such as time trade off and direct rating on visual analogue scales have been employed [12] . Alternatively, instruments such as the Health Utilities Index and the EuroQoL are specifically designed to estimate utilities. However, most quality of life instruments have not undergone the testing required to accurately convert their scores into utilities.
A simplified approach to integrate quality and quantity of life looks at the quality-adjusted time with and without symptoms or toxicity (Q-TWiST). It is particularly useful when looking at interventions that will have health effects persisting beyond the duration of treatment, such as adjuvant chemotherapy. In this case, the Q-TWiST is the sum of the quality adjusted (u) time spent undergoing treatment and experiencing toxicity (TOX), plus the time spent free of disease in perfect health (TWiST), plus the time spent experiencing symptoms in disease relapse (REL) [13] . It is calculated by the formula:
There is controversy around whether utilities should be derived from patients, their families, health care workers, or lay societal 'jurors' given detailed scenarios describing the health state. Recent guidelines favor the latter as being most consistent with a societal perspective [14] . However, there is concern that people without relevant disease experience may not properly understand the health (disease) state. Any one of these approaches to defining utilities is defensible, as long as it is stated clearly in the methods section of the publication.
Cost-benefit analysis
Cost-benefit analysis takes cost-utility analysis one step further. It tries to determine whether the benefits of an intervention outweigh its cost. As a result, cost-benefit analysis is in theory the gold standard of the different forms of economic evaluation. The quality-adjusted life years in the denominator are valued in monetary terms to arrive at the absolute benefit of the intervention. An intervention is 'cost-beneficial' if the benefits (measured in currency) are greater than the costs. Because these analyses always produce a monetary outcome, it is relatively easy to compare very different potential uses of resources. However, placing a monetary value on the often intangible outcomes of health care, in particular the value of a life, is problematic. As a result, true costbenefit analyses are rare.
Critical appraisal of an economic study
A source of frustration for the reader who is new to economic studies is that each one seems to use its own methodology. Such differences arise because researchers from varied backgrounds are addressing a wide range of health care interventions in diverse settings from different perspectives. Nevertheless, there are some key methodological principles that well-conducted studies should follow [15] [16] [17] . Policy makers in both Australia and the Province of Ontario (Canada) have proposed formal guidelines for the economic analyses that are to be part of drug reimbursement submissions [1, 2] . Furthermore, the 'Washington panel' recently published American guidelines for reporting economic studies [14] , and useful strategies have been proposed for critically appraising economic analyses [18, 19] . Table 2 summarizes important considerations when appraising economic studies. 
'Will my patients likely incur similar costs?'
Identification and assessment of costs and benefits
Depending on the perspective taken, the resource costs, or inputs, in an economic analysis can include:
-Direct treatment costs: the costs of resources used by the health sector to provide treatment (e.g. health care provider time, drugs, equipment, overhead). -Direct non treatment costs: the costs of resources used by patients and family to gain access to and participate in treatment, such as travel, parking, and accommodations near a cancer treatment centre. These often are measured by having patients complete diaries of out-of-pocket expenses. -Indirect costs: costs such as that of lost work time incurred by the patient, and family, friends, or volunteer organizations required for treatment. In accounting practice the term 'indirect cost' refers to overhead, but in health economics overhead is considered a direct cost. -Intangible costs: the costs of anxiety, uncertainty or pain caused by the treatment itself. These have proved difficult to measure. Techniques, such as 'willingness to pay' have been developed, but can be affected by each subject's own economic circumstance. It is important to ensure that the analysis has considered all relevant resources. These include both upfront and downstream costs. For example, when we analyzed the cost of treating lung cancer in Canada [20] , upfront costs included the costs of physician visits, diagnostic tests and procedures, hospitalization, as well as drugs and dispensing fees. Downstream costs included those for treatment complications and terminal care. One of these downstream costs, hospitalization for terminal care, turned out to be the largest single component of management over the entire course of illness.
If satisfied that all relevant resource use has been considered, it is important to assess whether they have been quantified accurately and valued credibly. One issue to consider is whether resource consumption data has been collected prospectively or retrospectively. Prospectively collected data, such as that gathered as part of a clinical trial, is desirable because it is more likely to be complete. It also allows for the timely availability of economic data to help decision-makers after an important clinical result is found. However, prospective data is more expensive to collect. Furthermore, care in clinical trials is often more resource intense than routine practice. For example, trials usually take place in expensive tertiary care teaching hospital settings, and involve more frequent monitoring with blood tests and imaging studies. As a result, retrospective data or prospective data collected outside a clinical trial can each be effectively used in many circumstances.
It is often preferable to determine costs in several steps, and to use a combination of empirical data and modeling in the analysis. Resource consumption data such as hospital days could first be gathered from a clinical trial. Then, this data could be adjusted to reflect anticipated usual care. For example, the frequency of imaging studies might be greater in a study situation than in routine practice. Lastly, the costs can be allocated to the resources consumed to calculate the cost of delivering the intervention. By separating resource consumption from cost, local variations in costs or charges can also be assessed in the analysis.
The time horizon considered in the analysis is also important. For example, the economic analysis of a Canadian trial of best supportive care versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC) found that patients receiving chemotherapy spent fewer days in hospital in the terminal phase of their illness, and required less palliative radiotherapy. This resulted in a net saving to the health care system [21] . An economic analysis that only covered the active treatment phase of the disease course might have reached a very different conclusion about the cost and cost-effectiveness of the treatment intervention.
Economic studies should distinguish between fixed and variable costs in their cost data. Each patient incurs the same fixed costs regardless of the total number of patients. Variable costs depend on volume and are subject to economies of scale. For variable costs, studies should measure marginal (or incremental) rather than average costs and benefits. Many studies use average costs as a proxy for marginal costs. However, care must be taken with this approach as the marginal and average costs may differ significantly in some cases. For example, in a breast screening program, the X-ray film and the radiologist's fee for reading each mammogram are fixed costs. However, the cost to the program of taking the mammogram is variable because the X-ray machines already exist and the technical staff are usually salaried. As a result, the marginal cost of screening an additional individual is likely to be significantly lower than the average cost (total cost divided by the number of patients).
There is controversy about how to value the indirect cost to society of lost working days. In the current economy of less than full employment in most developed countries, the loss of an employee does not really amount to the loss of that person's productivity to society. Another worker quickly replaces him from the ranks of the unemployed. Other employees commonly cover for short term absences. As a result, the only loss of productivity is in the time it takes to make these adjustments, the 'frictional unemployment' [22] . Unfortunately, this is very difficult to measure. As a result, economic analyses usually use an estimate of the actual wages lost as indirect costs. However, even this is controversial because it raises the possibility that treatments for diseases that affect children or the elderly will be undervalued because these groups do not usually participate in the workforce.
Some are of the opinion that leisure time should be valued as an indirect cost. Arguments against this say that such costs likely reflect the effectiveness of the intervention and its effect on quality of life. As a result, inclusion of the 'cost' of leisure time would result in 'double counting' the same information in both the numerator and the denominator of the cost-effectiveness ratio. While there is no consensus about what costs to include as indirect costs, reports should be clear about which elements they have included.
Setting
Economic evaluations are relatively specific to the health care system in which they are performed. Countries such as Canada have single payer universal health care systems in which the government funds virtually the entire system. As the administration of the health system is a provincial or territorial government responsibility, fees can still vary geographically within such a system, in part related to the wealth and politics of the region. In contrast, health care in the United States is funded by multiple payers, primarily private insurers, who compete for contracts to manage the care of groups of individuals. Charges for such care are influenced by market forces, government regulations, and taxation law [23] , and often bear little resemblance to actual incremental resource costs [24] . Medicare providers are required to provide cost-to-charge ratios which can be used to estimate costs. However, this approach assumes that these ratios are correct. A third type of system, common in European countries, provides universal health care with patients responsible for a co-payment. The differences amongst these systems make it difficult to translate the results of one economic study to a different health care system. Transparent and explicit presentation of the components of the evaluation is necessary in order to attempt such interpretation.
Discounting
Costs and benefits that occur in the future should be adjusted, or discounted, to their present value. This is because of 'time preference'. We generally prefer to incur benefits sooner rather than later and costs later rather than sooner. Thus, future costs and benefits have less weight than current costs and benefits, and are usually accounted for by applying a constant discount rate with the formula:
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where $ are the current cost, x is the discount rate, and n is the number of years over which it is discounted [16] . Such adjustment favors therapeutic procedures that provide immediate benefit, while rendering preventive and screening programs, which require immediate expenditure for future benefits, less attractive.
There is a lack of consensus over what the appropriate discount rate should be. Recent American guidelines suggest 3% [14] , while Canadian guidelines have recommended 5% [25] . The choice of discount rate can seriously affect the results of evaluations [26] , and so should be subject to sensitivity analysis. Also of debate is whether benefits and costs should be discounted at the same rate, as people do not seem to discount future health benefits as much as future costs [27] [28] [29] [30] .
'Will my patients likely derive similar benefits?'
Health care benefits, or outputs, can be measured as:
-direct benefits: monetary savings in treatment-related resource consumption, -indirect benefits: from reduction in productivity losses, and -intangible benefits: such as alleviation of pain and suffering associated with health improvements. As described previously, the type of study (cost-effectiveness, cost-utility etc.) will determine the type of benefit considered.
Large randomized controlled trials or meta-analyses provide the best measures of clinical effectiveness. However, extrapolation of economic and clinical data to routine practice is not always straightforward. Controlled clinical trials usually test the efficacy of a procedure under strictly defined 'ideal world' conditions. Differences in the demographic characteristics of the population, variations in clinical practice and availability of resources may mean that the procedure is less effective in routine clinical management [31] . For example, we might expect an elderly patient with multiple co-morbidities to have a very different experience with chemotherapy for advanced lung cancer than the highly selected patients studied in a clinical trial. A clinician must decide whether his patient is likely to derive the same benefits as the patients included in the study.
Similarly, toxicity of therapy may differ between the experimental and normal practice settings. The complication rate reported in a trial of complex therapy given to highly selected patients in a tertiary care setting may not be the same as that seen when the treatment is moved into general practice. As a result of the costs associated with these complications, the treatment might prove to be more expensive than predicted by the economic model.
When survival is the outcome of interest, it is important to accurately quantify the benefit. Because survival distributions are skewed, the median survival is most often reported in cancer trials. However, this measure may disregard important information when trying to determine the average benefit a patient can expect from a therapy. For example, an intervention that results in some cures will create a long tail on the survival curve and contribute to the number of life years gained. Such an intervention can be highly cost-effective, even if there is little or no increase in the median survival time ( Figure 1) . As a result, economic evaluations should use the area between two survival curves to determine the average benefit from treatment.
'Is the intervention cost-effective?'
Thresholds
The cost-effectiveness ratio (CE) is the incremental cost of an intervention divided by its incremental benefits, as given by the formula:
where C represents the cost of each intervention and E represents effectiveness. What constitutes a cost-effective intervention? There are two types of decision rules to determine cost-effectiveness. One is to have a threshold for determining acceptable interventions. Canadian authors have proposed that interventions costing less than 520,000 per QALY be considered cost-effective [32] . Americans tend to set the threshold at approximately $50,000 per QALY [23] . These cutpoints are arbitrary. The argument for having a cutoff similar to the cost-effectiveness of hemodialysis comes from the fact that the US Congress debated its funding when it was first introduced. The decision to fund hemodialysis is held up as a precedent for society to fund similarly cost-effective programs.
League tables
The other type of decision rule is a 'league table'. Economic evaluations assume that resources are limited, and have alternative uses if not applied to the intervention in question. Policy makers must make decisions that will maximize health by getting the highest value However, because some patients are cured, there is a plateau on the tail of the curve that may eventually produce a larger increase in the area between the two, even if the benefits are discounted.
for the resources consumed. Their decisions often reflect a utilitarian philosophy of doing the greatest good for the greatest number of people. In order to do this, a technology must be assessed for its efficiency relative to all other potential uses of the same resources. The value of an intervention if its resources were put towards the best alternative use is called its opportunity cost. This approach considers not only patients with diseases, but all potential patients in society as the beneficiaries of health funding decisions.
Cost-effectiveness league tables such as Table 3 rank interventions by cost per life year or cost per QALY gained. There are two major attractions to league tables: they place results in the context of the cost-effectiveness of other technologies; and they offer an easy mechanism to inform or justify resource allocation decisions. Resources can then be spent on the most cost-effective programs until the resources are exhausted. specialties [33] [34] [35] , and in oncology in particular [36] . However, there are many methodological difficulties in creating league tables, necessitating caution when using them for resource allocation [37] . One major problem is that they often group together studies that were undertaken in different years. Generally the costeffectiveness figures will be adjusted to a base year, but this requires assumptions of constancy of relative costs, resource use, disease management, and treatment efficacy over time.
Further problems in the use of league tables relate to potential differences in study methodology. Methodological differences include the choice of treatment comparisons, the length of follow-up of patients, the quality of life or utility instrument adopted, the assumptions made, and the range and sources of costs included [37] . Such differences may affect the ranking of various technologies within a league table thus leading to erroneous conclusions.
Both the threshold and league table approaches assume that QALYs have the same value in all situations. However, empirical evidence tells us otherwise. Society generally adheres to the 'rule of rescue'. We are more willing to pay for an intervention that will save an identifiable life, such as an individual who requires a heart transplant, than one for which a 'statistical' life may be saved, as in preventive programs. Because of these problems, neither league tables nor thresholds should be seen as providing the answer to difficult resource allocation decisions. Rather they should be seen as an aid to decision-makers. 
Risk of bias
Because there are so many variables in economic analyses that an investigator can choose to include or exclude in a study, there is always the possibility of bias. Some data may be unavailable, some may be from trials with highly selected patients, and some may be consciously or subconsciously ignored. Because of these pitfalls, readers of economic analyses must be especially critical of studies sponsored by pharmaceutical companies, as industry has a strong interest in seeing these studies come out in favor of its products.
Transparency
A concern with many economic papers is a lack of transparency in the description of methods and assumptions. Transparency refers to how easy it is to see exactly what the authors of a study have done. After reading the results of an economic analysis, the reader should not be left with the impression that the study was done in a 'black box'. It is best to report disaggregated data on costs, resource use, and quality of life [38] . For example, the numerator and denominator of cost-effectiveness ratios should be reported separately. Costs should be shown in the format: quantity x unit price = cost, while effectiveness measures should be separated from their utility weightings. Obviously, it is important to know the currency and year of the costs. However, reports should also identify instances of price adjustment, such as use of the consumer price index to inflate prices from another time period, or the date and exchange rate used to translate costs from other countries.
Greater transparency will facilitate the use of studies by decision-makers. A relevant, well-done study presented in a transparent fashion should even make it possible for physicians to use local costs to estimate the cost-effectiveness of a particular intervention in their own environment using common spreadsheet software. They could also create league tables in their region to inform local decisions [39] .
Sensitivity analysis
Standard statistical techniques usually cannot be used to look for differences between the arms of an economic study [40] . Economic endpoints often require larger sample sizes than clinical endpoints due to variation in economic parameters, such as length of hospital stay, that are not controlled for by inclusion or exclusion criteria. Therefore, detailed sensitivity analyses should be conducted. Such analyses assess how sensitive the study results are to varying the estimates of resource use and effectiveness over a range of plausible possibilities. No matter how accurately costs and benefits have been quantified and valued, it is likely that certain assumptions have been made along the way. Skeptics often attack these assumptions to dismiss a study.
Thus, for an economic evaluation to be considered sound, it is necessary to test the effect of changes in these assumptions. If altering the value of key parameters changes the conclusion of the study, it is 'sensitive' to those parameters, and not 'robust'. For example, in our cost-effectiveness study of vinorelbine in stage IV NSCLC [41] , we did sensitivity analyses around the number of cycles of chemotherapy given, the number of hospital days for treatment and palliative care, and the amount of survival gained. These showed that the initial conclusion was robust, in that the treatment was still within acceptable boundaries of cost-effectiveness even using extreme assumptions. The question becomes not whether all estimates of resource use and survival were accurate, but whether any errors would have a meaningful impact on the results.
Conclusion
Health care innovations are usually more effective and/or less toxic than previous treatments. However, administrators sometimes have trouble seeing past the price of these interventions. Clinicians may be given the option of using new treatments, provided they are paid for out of a fixed operating budget. This puts the onus on the physician to decide the best use of resources in his/ her own practice, while allowing flexibility around the introduction of new technologies. It is important that physicians understand how to assess these technologies in the broader context of the costs and consequences associated with their use. By providing decision-makers with useful information from methodologically sound studies, physicians can be more effective advocates for treatments of benefit to their patients.
